We are live on ! Find out more
ENZN

ENZON PHARMACEUTICALS INC
ENZN

Delisted

ENZN was delisted on the 19th of May, 2016.

Back to rankings

57 hedge funds and large institutions have $21.1M invested in ENZON PHARMACEUTICALS INC in 2014 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 22 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% less funds holding

Funds holding: 65 → 57 (-8)

14% less capital invested

Capital invested by funds: $24.6M → $21.1M (-$3.5M)

45% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 22

58% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 12

Holders
57
Holders Change
-8
Holders Change %
-12.31%
% of All Funds
1.52%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
12
Reduced
22
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$245K
2
California Public Employees Retirement System
California Public Employees Retirement System
California
+$119K
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$59K
4
KBC Group
KBC Group
Belgium
+$55.6K
5
Invesco
Invesco
Georgia
+$16.9K

Top Sellers

Rank Fund Capital Flow
1
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$1.19M
2
Schroder Investment Management Group
Schroder Investment Management Group
United Kingdom
-$957K
3
MFP
Michael F. Price
-$367K
4
FPA
First Pacific Advisors
California
-$339K
5
MERSOM
Municipal Employees' Retirement System of Michigan
Michigan
-$324K
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$123K +$617 +588 +0.5%
GC
27
Globeflex Capital
California
$110K -$125 -119 -0.1%
CS
28
Credit Suisse
Switzerland
$104K -$5.36K -5,104 -5%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$104K +$361 +344 +0.4%
VKH
30
Virtu KCG Holdings
New York
$60K +$15.2K +14,501 +36%
Tudor Investment Corp
31
Tudor Investment Corp
Connecticut
$52K – – –
KBC Group
32
KBC Group
Belgium
$52K +$55.6K +52,981 New
RCM
33
Rotella Capital Management
Washington
$40K -$17K -16,188 -30%
BJ
34
BlackRock Japan
Japan
$38K -$3.19K -3,036 -8%
State Street
35
State Street
Massachusetts
$36K -$2.52K -2,400 -7%
FPA
36
First Pacific Advisors
California
$26K -$339K -323,409 -93%
Charles Schwab
37
Charles Schwab
California
$24K – – –
TRCT
38
Tower Research Capital (TRC)
New York
$23K -$13.2K -12,612 -37%
Ameriprise
39
Ameriprise
Minnesota
$17K -$294 -280 -2%
AL
40
Airain Ltd
Guernsey
$11K -$7.15K -6,811 -40%
MCM
41
Monarch Capital Management
Indiana
$11K – – –
SCP
42
Seizert Capital Partners
Michigan
$11K +$10.5K +10,000 New
Federated Hermes
43
Federated Hermes
Pennsylvania
$10K – – –
CFA
44
CT Financial Advisors
Pennsylvania
$3.26K +$3.14K +2,990 New
Group One Trading
45
Group One Trading
Illinois
$2K -$19.3K -18,402 -90%
KTC
46
Kistler-Tiffany Companies
Pennsylvania
$1K – – –
NFG
47
Next Financial Group
Texas
$1K – – –
WT
48
Whittier Trust
California
$1K – – –
Wells Fargo
49
Wells Fargo
California
$1K +$1 +1 +0.1%
Manulife (Manufacturers Life Insurance)
50
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2 -$1.27K -1,215 -41%
1
2
3

ENZN Hedge Fund Activity: Q4 2014 in Review

57 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in ENZON PHARMACEUTICALS INC (ENZN) for Q4 2014, worth a combined $21.1M — down 14% from $24.6M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of ENZN and 5 opened new positions — a net loss of 7 holders — while 22 trimmed existing stakes and 12 added.

The largest buyer was Renaissance Technologies, adding an estimated $245K. The largest seller was Dimensional Fund Advisors, exiting entirely with an estimated $1.19M sold.

  • 57 institutional investors held ENZON PHARMACEUTICALS INC (ENZN) as of Q4 2014, down from 65 in Q3 2014.
  • Funds reported $21.1M of ENZON PHARMACEUTICALS INC stock for Q4 2014, down 14% quarter-over-quarter.
  • 5 funds opened new ENZON PHARMACEUTICALS INC positions in Q4 2014 and 12 closed out, a net change of -7 holders.
  • The largest ENZON PHARMACEUTICALS INC buyer in Q4 2014 was Renaissance Technologies, an estimated $245K added.
  • The largest ENZON PHARMACEUTICALS INC seller in Q4 2014 was Dimensional Fund Advisors, an estimated $1.19M sold.

Based on aggregated 13F filings for Q4 2014.